Bionano Genomics announces publication reporting first use of OGM to detect CAG

Bionano Genomics (BNGO) announced a study published in the American Journal of Hematology demonstrating the potential utility of optical genome mapping, OGM, for detecting structural variants associated with chromoanagenesis, CAG, in acute myeloid leukemia. CAG is a catastrophic genomic event that is frequently associated with highly complex karyotypes, extensive clonal heterogeneity, treatment resistance, and poor prognosis compared to subjects with no detectable CAG. Based on the OGM findings, clinical researchers found higher than anticipated rates of CAG in AML, suggesting that OGM may be more sensitive than traditional cytogenetic methods in identifying aggressive forms of AML.